Literature DB >> 10862203

Prognostic significance of proliferative activity in pN2 non-small-cell lung carcinomas and their mediastinal lymph node metastases.

T Fukuse1, T Hirata, H Naiki, S Hitomi, H Wada.   

Abstract

OBJECTIVE: To investigate the expression of proliferating cell nuclear antigen (PCNA) in both primary tumor and lymph node metastases of pathologic stage IIIA N2 non-small-cell lung carcinoma (NSCLC) and the relation to prognosis. SUMMARY BACKGROUND DATA: Although the prognosis of pN2 NSCLC is poor in general, long-term survivors have been reported among patients with completely resected or clinical N0 disease and those with skip metastasis. However, few reports are available on preoperative prognostic predictors. Expression of PCNA is known to be associated with tumor proliferation and is correlated with the prognosis of several carcinomas.
METHODS: Clinicopathologic factors were investigated in relation to prognosis in 76 patients with pathologic stage IIIA pN2 NSCLC from whom resected surgical specimens were available from both the primary tumor and lymph node metastases for evaluation of PCNA expression.
RESULTS: A significant correlation was observed between PCNA labeling index in the primary tumor and that in lymph node metastases. The prognosis in patients with PCNA-negative primary tumor (5-year survival rate, 66.0%) was significantly more favorable than that of patients with PCNA-positive primary tumor (5-year survival rate, 21.5%). The prognosis in patients with PCNA-negative metastases was significantly more favorable than that of patients with PCNA-positive metastases. For clinical N2 disease also, the prognosis of patients with PCNA-negative primary tumor was favorable (5-year survival rate, 66.1%). Multivariate analyses showed that PCNA expression and complete resection were significant prognostic factors.
CONCLUSIONS: Preoperatively diagnosed N2 NSCLC exhibiting negative PCNA expression in primary tumor or lymph node metastases is expected to result in a favorable postoperative prognosis and may be an indication for primary resection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10862203      PMCID: PMC1421115          DOI: 10.1097/00000658-200007000-00016

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  28 in total

1.  Relation of neovascularisation to metastasis of non-small-cell lung cancer.

Authors:  P Macchiarini; G Fontanini; M J Hardin; F Squartini; C A Angeletti
Journal:  Lancet       Date:  1992-07-18       Impact factor: 79.321

2.  Aggressive surgical intervention in N2 non-small cell cancer of the lung.

Authors:  Y Watanabe; J Shimizu; M Oda; Y Hayashi; S Watanabe; Y Tatsuzawa; T Iwa; M Suzuki; T Takashima
Journal:  Ann Thorac Surg       Date:  1991-02       Impact factor: 4.330

Review 3.  Tumor cell intravasation alu-cidated: the chick embryo opens the window.

Authors:  J P Quigley; P B Armstrong
Journal:  Cell       Date:  1998-08-07       Impact factor: 41.582

4.  The role of surgery in N2 lung cancer.

Authors:  N Martini; B J Flehinger
Journal:  Surg Clin North Am       Date:  1987-10       Impact factor: 2.741

5.  Five-year survivors with resected pN2 nonsmall cell lung carcinoma.

Authors:  M Sagawa; A Sakurada; S Fujimura; M Sato; S Takahashi; K Usuda; C Endo; H Aikawa; T Kondo; Y Saito
Journal:  Cancer       Date:  1999-02-15       Impact factor: 6.860

6.  Comparison of DNA content in gastric cancer cells between primary lesions and lymph node metastases.

Authors:  H Baba; D Korenaga; T Okamura; K Sugimachi
Journal:  Cancer       Date:  1990-10-15       Impact factor: 6.860

7.  The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer.

Authors:  G Fontanini; P Macchiarini; S Pepe; A Ruggiero; M Hardin; D Bigini; S Vignati; R Pingitore; C A Angeletti
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

8.  Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.

Authors:  R Bravo; R Frank; P A Blundell; H Macdonald-Bravo
Journal:  Nature       Date:  1987 Apr 2-8       Impact factor: 49.962

9.  Prognostic significance of computed tomography in resected N2 lung cancer.

Authors:  I J Cybulsky; L A Lanza; M B Ryan; J B Putnam; M M McMurtrey; J A Roth
Journal:  Ann Thorac Surg       Date:  1992-09       Impact factor: 4.330

Review 10.  Surgical treatment for higher stage non-small cell lung cancer.

Authors:  D E Van Raemdonck; A Schneider; R J Ginsberg
Journal:  Ann Thorac Surg       Date:  1992-11       Impact factor: 4.330

View more
  5 in total

Review 1.  18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.

Authors:  G Laking; P Price
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 2.  UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.

Authors:  Fumihiro Tanaka
Journal:  Surg Today       Date:  2007-10-25       Impact factor: 2.549

3.  Immunophenotypic features of metastatic lymph node tumors to predict recurrence in N2 lung squamous cell carcinoma.

Authors:  Rie Matsuwaki; Genichiro Ishii; Yoshitaka Zenke; Shinya Neri; Keiju Aokage; Tomoyuki Hishida; Junji Yoshida; Satoshi Fujii; Haruhiko Kondo; Tomoyuki Goya; Kanji Nagai; Atsushi Ochiai
Journal:  Cancer Sci       Date:  2014-07-01       Impact factor: 6.716

4.  Metastatic Patterns of Mediastinal Lymph Nodes in Small-Size Non-small Cell Lung Cancer (T1b).

Authors:  Yijun Wu; Chang Han; Liang Gong; Zhile Wang; Jianghao Liu; Xinyu Liu; Xinyi Chen; Yuming Chong; Naixin Liang; Shanqing Li
Journal:  Front Surg       Date:  2020-09-22

5.  The Significance of Skip Mediastinal Lymph Node Metastasis in the Prognosis of Patients with Resected Non-Small-Cell Lung Carcinoma: Is It Really a Better N2 Disease Subtype?

Authors:  Yunus Seyrek; Levent Cansever; Hasan Akın; Muzaffer Metin; Erkut Bolat; Mehmet Ali Bedirhan
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-03-31       Impact factor: 1.520

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.